BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyatake S, Shimizu-Motohashi Y, Takeda S, Aoki Y. Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Des Devel Ther 2016;10:2745-58. [PMID: 27621596 DOI: 10.2147/DDDT.S110163] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Kaziród K, Myszka M, Dulak J, Łoboda A. Hydrogen sulfide as a therapeutic option for the treatment of Duchenne muscular dystrophy and other muscle-related diseases. Cell Mol Life Sci 2022;79:608. [DOI: 10.1007/s00018-022-04636-0] [Reference Citation Analysis]
2 Fujikura Y, Yamanouchi K, Sugihara H, Hatakeyama M, Abe T, Ato S, Oishi K. Ketogenic diet containing medium-chain triglyceride ameliorates transcriptome disruption in skeletal muscles of rat models of duchenne muscular dystrophy. Biochemistry and Biophysics Reports 2022;32:101378. [DOI: 10.1016/j.bbrep.2022.101378] [Reference Citation Analysis]
3 Deng J, Zhang J, Shi K, Liu Z. Drug development progress in duchenne muscular dystrophy. Front Pharmacol 2022;13:950651. [DOI: 10.3389/fphar.2022.950651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Guo Z, Geng M, Huang Y, Han G, Jing R, Lin C, Zhang X, Zhang M, Fan G, Wang F, Yin H. Upregulation of Wilms' Tumor 1 in epicardial cells increases cardiac fibrosis in dystrophic mice. Cell Death Differ 2022. [PMID: 35306537 DOI: 10.1038/s41418-022-00979-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang S, Yang J, Zhao H, Deng R, Fan H, Zhang J, Yang Z, Zeng H, Kuang B, Shao L. The Protective Effects of γ-Tocotrienol on Muscle Stem Cells Through Inhibiting Reactive Oxidative Stress Production. Front Cell Dev Biol 2022;10:820520. [DOI: 10.3389/fcell.2022.820520] [Reference Citation Analysis]
6 Tripodi L, Villa C, Molinaro D, Torrente Y, Farini A. The Immune System in Duchenne Muscular Dystrophy Pathogenesis. Biomedicines 2021;9:1447. [PMID: 34680564 DOI: 10.3390/biomedicines9101447] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
7 Tulangekar A, Sztal TE. Inflammation in Duchenne Muscular Dystrophy-Exploring the Role of Neutrophils in Muscle Damage and Regeneration. Biomedicines 2021;9:1366. [PMID: 34680483 DOI: 10.3390/biomedicines9101366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Ali AM, Kunugi H. Physical Frailty/Sarcopenia as a Key Predisposing Factor to Coronavirus Disease 2019 (COVID-19) and Its Complications in Older Adults. BioMed 2021;1:11-40. [DOI: 10.3390/biomed1010002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
9 Dias RM, Hoshi RA, Vanderlei LCM, Monteiro CBM, Alvarez MPB, Crocetta TB, Grossklauss LF, Fernani DCGL, Dantas MTAP, Martins FPA, Garner DM, Abreu LC, Ferreira C, da Silva TD. Influence of Different Types of Corticosteroids on Heart Rate Variability of Individuals with Duchenne Muscular Dystrophy-A Pilot Cross Sectional Study. Life (Basel) 2021;11:752. [PMID: 34440496 DOI: 10.3390/life11080752] [Reference Citation Analysis]
10 Raimondo TM, Mooney DJ. Anti-inflammatory nanoparticles significantly improve muscle function in a murine model of advanced muscular dystrophy. Sci Adv 2021;7:eabh3693. [PMID: 34162554 DOI: 10.1126/sciadv.abh3693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
11 Péladeau C, Sandhu JK. Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases. Int J Mol Sci 2021;22:6068. [PMID: 34199845 DOI: 10.3390/ijms22116068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Mareedu S, Million ED, Duan D, Babu GJ. Abnormal Calcium Handling in Duchenne Muscular Dystrophy: Mechanisms and Potential Therapies. Front Physiol 2021;12:647010. [PMID: 33897454 DOI: 10.3389/fphys.2021.647010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 23.0] [Reference Citation Analysis]
13 Frinchi M, Morici G, Mudó G, Bonsignore MR, Di Liberto V. Beneficial Role of Exercise in the Modulation of mdx Muscle Plastic Remodeling and Oxidative Stress. Antioxidants (Basel) 2021;10:558. [PMID: 33916762 DOI: 10.3390/antiox10040558] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
14 Ma J, Beers B, Manohar R, Roe S, Colacino JM, Kong R. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort. Pharmacol Res Perspect 2021;9:e00748. [PMID: 33749127 DOI: 10.1002/prp2.748] [Reference Citation Analysis]
15 Howard ZM, Lowe J, Blatnik AJ 3rd, Roberts D, Burghes AHM, Bansal SS, Rafael-Fortney JA. Early Inflammation in Muscular Dystrophy Differs between Limb and Respiratory Muscles and Increases with Dystrophic Severity. Am J Pathol 2021;191:730-47. [PMID: 33497702 DOI: 10.1016/j.ajpath.2021.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
16 Vita GL, Sframeli M, Licata N, Bitto A, Romeo S, Frisone F, Ciranni A, Pallio G, Mannino F, Aguennouz M, Rodolico C, Squadrito F, Toscano A, Messina S, Vita G. A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sci 2021;11:115. [PMID: 33467104 DOI: 10.3390/brainsci11010115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
17 Nagasaka M, Taniguchi-ikeda M. Muscular Dystrophy. Fetal Morph Functional Diagnosis 2021. [DOI: 10.1007/978-981-15-8171-7_8] [Reference Citation Analysis]
18 Łoboda A, Dulak J. Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. Pharmacol Rep 2020;72:1227-63. [PMID: 32691346 DOI: 10.1007/s43440-020-00134-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 14.0] [Reference Citation Analysis]
19 Zschüntzsch J, Jouvenal PV, Zhang Y, Klinker F, Tiburcy M, Liebetanz D, Malzahn D, Brinkmeier H, Schmidt J. Long-term human IgG treatment improves heart and muscle function in a mouse model of Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle 2020;11:1018-31. [PMID: 32436338 DOI: 10.1002/jcsm.12569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Péladeau C, Adam N, Bronicki LM, Coriati A, Thabet M, Al-Rewashdy H, Vanstone J, Mears A, Renaud JM, Holcik M, Jasmin BJ. Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles. Nat Commun 2020;11:1990. [PMID: 32332749 DOI: 10.1038/s41467-020-15971-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
21 Jin Y, Shen Y, Su X, Weintraub NL, Tang Y. Effective restoration of dystrophin expression in iPSC Mdx-derived muscle progenitor cells using the CRISPR/Cas9 system and homology-directed repair technology. Comput Struct Biotechnol J 2020;18:765-73. [PMID: 32280431 DOI: 10.1016/j.csbj.2020.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
22 Gilchrist JM, Donahue JE. Immunologic Disorders of Neuromuscular Junction and Muscle. Clinical Neuroimmunology 2020. [DOI: 10.1007/978-3-030-24436-1_15] [Reference Citation Analysis]
23 Lombardo SD, Mazzon E, Mangano K, Basile MS, Cavalli E, Mammana S, Fagone P, Nicoletti F, Petralia MC. Transcriptomic Analysis Reveals Involvement of the Macrophage Migration Inhibitory Factor Gene Network in Duchenne Muscular Dystrophy. Genes (Basel) 2019;10:E939. [PMID: 31752120 DOI: 10.3390/genes10110939] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
24 Miyatake S, Mizobe Y, Tsoumpra MK, Lim KRQ, Hara Y, Shabanpoor F, Yokota T, Takeda S, Aoki Y. Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle. Mol Ther Nucleic Acids 2019;14:520-35. [PMID: 30763772 DOI: 10.1016/j.omtn.2019.01.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
25 Vita GL, Polito F, Oteri R, Arrigo R, Ciranni AM, Musumeci O, Messina S, Rodolico C, Di Giorgio RM, Vita G, Aguennouz M. Hippo signaling pathway is altered in Duchenne muscular dystrophy. PLoS One 2018;13:e0205514. [PMID: 30304034 DOI: 10.1371/journal.pone.0205514] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
26 Barker RG, van der Poel C, Horvath D, Murphy RM. Taurine and Methylprednisolone Administration at Close Proximity to the Onset of Muscle Degeneration Is Ineffective at Attenuating Force Loss in the Hind-Limb of 28 Days Mdx Mice. Sports (Basel) 2018;6:E109. [PMID: 30274388 DOI: 10.3390/sports6040109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
27 Iannotti FA, Pagano E, Moriello AS, Alvino FG, Sorrentino NC, D'Orsi L, Gazzerro E, Capasso R, De Leonibus E, De Petrocellis L, Di Marzo V. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. Br J Pharmacol 2019;176:1568-84. [PMID: 30074247 DOI: 10.1111/bph.14460] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
28 Cordova G, Negroni E, Cabello-Verrugio C, Mouly V, Trollet C. Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy. Front Genet 2018;9:114. [PMID: 29692797 DOI: 10.3389/fgene.2018.00114] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
29 Hagan M, Ashraf M, Kim IM, Weintraub NL, Tang Y. Effective regeneration of dystrophic muscle using autologous iPSC-derived progenitors with CRISPR-Cas9 mediated precise correction. Med Hypotheses 2018;110:97-100. [PMID: 29317080 DOI: 10.1016/j.mehy.2017.11.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
30 Wada E, Tanihata J, Iwamura A, Takeda S, Hayashi YK, Matsuda R. Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice. Skelet Muscle 2017;7:23. [PMID: 29078808 DOI: 10.1186/s13395-017-0140-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
31 Pinniger GJ, Terrill JR, Assan EB, Grounds MD, Arthur PG. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy. J Physiol 2017;595:7093-107. [PMID: 28887840 DOI: 10.1113/JP274229] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
32 Mornet D, Rivier F. Quel avenir pour la dystrophine ? Cah Myol 2017. [DOI: 10.1051/myolog/201715017] [Reference Citation Analysis]
33 Baker DE. Eteplirsen. Hosp Pharm 2017;52:302-5. [PMID: 28515510 DOI: 10.1310/hpj5204-302] [Cited by in F6Publishing: 1] [Reference Citation Analysis]